登录新浪财经APP 搜索【信披】查看更多考评等级 西部超导材料科技股份有限公司于2025年8月26日收到陕西证监局出具的行政监管措施决定书，公司及 董事长冯勇等4人因多项违规问题被采取责令改正、出具警示函措施。 收入核算不规范致2024年财报数据披露不准 陕西证监局检查发现，西部超导2024年对个别客户收入确认不及时，导致公司2024年财务报表相关数据 披露不准确。这一事项不符合《企业会计准则 - 基本准则》第十九条规定，反映出公司销售业务相关内 部控制运行不规范。 募集资金管理存空窗期操作 因未将属于某同一控制人控制的客户在年报中合并列示，以及对个别客户收入确认不及时，西部超导 2024年年度报告前五大客户金额、占比等披露不准确，不符合《公开发行证券的公司信息披露内容与格 式准则第2号 - 年度报告的内容与格式》规定。 陕西证监局认定，上述事项违反《上市公司信息披露管理办法》相关规定，董事长冯勇、总经理杜予 晅、财务总监李魁芳、董事会秘书王凯旋对违规事项负有主要责任，因此对公司采取责令改正措施，并 对上述4人采取出具警示函措施，要求公司30日内提交书面整改报告。 西部超导表示，公司及相关人员高度重视问题，将 ...

Core Viewpoint - The announcement details the regulatory measures and penalties faced by Borui Biopharmaceuticals (Suzhou) Co., Ltd. over the past five years, emphasizing the company's commitment to compliance and governance improvements. Recent Regulatory Penalties - The company and its directors, supervisors, and senior management have not faced any penalties from regulatory authorities in the last five years [1] Recent Regulatory Measures and Rectification - On February 13, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the company's announcement on antiviral drug research progress, requiring clarification on the commercialization timeline and potential patent infringements related to the production of remdesivir [2] - The company responded that the remdesivir project is still in the preclinical research stage and that its production is limited to research purposes, thus not infringing on Gilead's patents [2][3] - On March 1, 2020, the Shanghai Stock Exchange issued a decision to place the company under regulatory scrutiny due to unclear information disclosure regarding the distinction between experimental production and commercial production [4] - The former board secretary was criticized for further confusing the terms during a media interview, leading to regulatory actions against him [5] - On March 11, 2020, the Jiangsu Securities Regulatory Bureau issued a warning letter, confirming that the company's disclosure of "batch production" was misleading and did not accurately reflect the drug development progress [7] - On June 30, 2020, the Shanghai Stock Exchange issued a regulatory work letter regarding the establishment of an investment fund, requiring the company to enhance internal control mechanisms and ensure compliance in external investments [8] - On October 17, 2023, a warning letter was issued to an individual for misleading statements regarding a product still in clinical trials, emphasizing the need for accurate information disclosure [9] - On June 20, 2025, a warning letter was issued due to the company's failure to timely redeem idle fundraising cash management products, violating disclosure obligations [10][12] - The company has committed to improving compliance and internal management practices in response to these regulatory measures [11][14]

4月1日晚间，塞力医疗连发三条公告。因未按期归还暂时补流的募集资金，塞力医疗被上海证交所通报 批评并被湖北证监局责令改正；因未按规定披露关联交易及大股东资金占用情况，未按规定披露重要合 同订立事项，塞力医疗遭湖北证监局行政处罚。 累计未归还募集资金4.68亿元 经查，塞力医疗于2024年7月27日前未按期归还暂时补流的募集资金8200万元，于2024年8月29日前未按 期归还暂时补流的募集资金3.74亿元，于2025年1月8日前未按期归还暂时补流的募集资金5000万元，并 导致2023年7月27日、2023年8月29日和2024年1月8日披露的信息"使用期限不超过12个月"与实际不符。 根据相关公告，塞力医疗于2024年12月30日归还800万元至募集资金专用账户，于2025年2月27日归还 3000万元至募集资金专用账户。截至2025年2月28日，塞力医疗累计未归还募集资金合计为4.68亿元。 上海证交所认为，塞力医疗将多笔闲置募集资金用于暂时补充流动资金，均未在规定期限内及时归还， 且所涉金额较大，上述行为违反了相关规定；时任董事长温伟作为公司主要负责人，时任总经理王政作 为公司日常经营管理的具体负责人， ...